Pacira Pharma (PCRX) Tops Q4 EPS by 28c

Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.38, $0.28 better than the analyst estimate of $0.10. Revenue for the quarter came in at $79.1 million versus the consensus estimate of $79.32 million.

2018 Outlook

Pacira announces its full year 2018 financial guidance as follows. Pacira expects:

• EXPAREL net product sales of $300 million to $310 million.
• Non-GAAP gross margins of 70% to 72%.
• Non-GAAP research and development (R&D) expense of $50 million to $60 million.
• Non-GAAP selling, general and administrative (SG&A) expense of $150 million to $160 million.
• Stock-based compensation of $30 million to $35 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal